Biscryptolepine

Biscryptolepine

SCHEMBL30192568

Cn1c2c3ccccc3nc-2c(-c2c3nc4ccccc4c-3n(C)c3ccccc23)c2ccccc21

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 1/20 0.54
GPR3 P46089 1/20 0.47
ALDH1A1 P00352 4/20 0.46
KDM4E B2RXH2 4/20 0.46
HPGD P15428 2/20 0.46
GAA P10253 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 4/20 0.42
HSD17B10 Q99714 4/20 0.41
NTRK1 P04629 1/20 0.41
CYP2C19 P33261 1/20 0.41
ATM Q13315 1/20 0.41
POLB P06746 2/20 0.40
MAPT P10636 2/20 0.40
TP53 P04637 1/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
CYP11B2 P19099 1/20 0.40
GSR P00390 1/20 0.39
NPC1 O15118 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3291144 0.84 TERT (0.53) TERTGPR3ALDH1A1KDM4EHPGD
SCHEMBL3291028 0.83 TERT (0.51) TERTGPR3ALDH1A1KDM4EHPGD
SCHEMBL8480481 0.83 TERT (0.51) TERTGPR3ALDH1A1KDM4EHPGD
Hydrochloric Acid SCHEMBL8480513 0.81 TERT (0.50) TERTGPR3ALDH1A1KDM4EHPGD
Hydrochloric Acid SCHEMBL8485102 0.81 TERT (0.50) TERTGPR3ALDH1A1KDM4EHPGD
Iodide SCHEMBL8482236 0.81 TERT (0.50) TERTGPR3ALDH1A1KDM4EHPGD
SCHEMBL3290155 0.79 EGFR (0.55) TERTALDH1A1KDM4EHPGDGAA
Hydrochloric Acid SCHEMBL8485731 0.78 EGFR (0.54) TERTALDH1A1KDM4EHPGDGAA
Hydrochloric Acid SCHEMBL8482280 0.77 MEN1 (0.52) TERTALDH1A1KDM4EHPGDGAA
SCHEMBL8479763 0.75 GABRP (0.53) TERTALDH1A1KDM4EHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250213601-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES Didenko, Kirill (US) 2025-07-03 US disclosed
WO-2024189607-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT DIDENKO KIRILL (MX) 2024-09-19 WO disclosed
WO-2023187599-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES DIDENKO KIRILL (MX) 2023-10-05 WO disclosed
WO-2023037254-A1 METHODS AND COMPOUNDS FOR TREATING CORONAVIRIDAE VIRUS INFECTIONS DIDENKO KIRILL (MX) 2023-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250213601-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES ACE2, FURIN, SARS1 TERT 693/4885GPR3 4469/4885ALDH1A1 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.